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Abstract
Background: Stage at diagnosis plays a significant role in colorectal cancer (CRC) survival.
Understanding which factors contribute to a more advanced stage at diagnosis is vital to improving
overall survival. Comorbidity, race, and age are known to impact receipt of cancer therapy and
survival, but the relationship of these factors to stage at diagnosis of CRC is less clear. The objective
of this study is to investigate how comorbidity, race and age influence stage of CRC diagnosis.
Methods: Two distinct healthcare populations in the United States (US) were retrospectively
studied. Using the Cancer Care Outcomes Research and Surveillance Consortium database, we
identified CRC patients treated at 15 Veterans Administration (VA) hospitals from 2003–2007. We
assessed metastatic CRC patients treated from 2003–2006 at 10 non-VA, fee-for-service (FFS)
practices. Stage at diagnosis was dichotomized (non-metastatic, metastatic). Race was
dichotomized (white, non-white). Charlson comorbidity index and age at diagnosis were calculated.
Associations between stage, comorbidity, race, and age were determined by logistic regression.
Results: 342 VA and 340 FFS patients were included. Populations differed by the proportion of
patients with metastatic CRC at diagnosis (VA 27% and FFS 77%) reflecting differences in eligibility
criteria for inclusion. VA patients were mean (standard deviation; SD) age 67 (11), Charlson index
2.0 (1.0), and were 63% white. FFS patients were mean age 61 (13), Charlson index 1.6 (1.0), and
were 73% white. In the VA cohort, higher comorbidity was associated with earlier stage at
diagnosis after adjusting for age and race (odds ratio (OR) 0.76, 95% confidence interval (CI) 0.58–
1.00; p = 0.045); no such significant relationship was identified in the FFS cohort (OR 1.09, 95% CI
0.82–1.44; p = 0.57). In both cohorts, no association was found between stage at diagnosis and
either age or race.
Published: 25 November 2008
BMC Cancer 2008, 8:345 doi:10.1186/1471-2407-8-345
Received: 3 June 2008
Accepted: 25 November 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/345
© 2008 Zafar et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:345 http://www.biomedcentral.com/1471-2407/8/345Conclusion: Higher comorbidity may lead to earlier stage of CRC diagnosis. Multiple factors,
perhaps including increased interactions with the healthcare system due to comorbidity, might
contribute to this finding. Such increased interactions are seen among patients within a healthcare
system like the VA system in the US versus sporadic interactions which may be seen with FFS
healthcare.
Background
CRC is the second most common cancer in Europe and
the fourth most common cancer in the United States (US)
[1,2]. CRC is the second leading cause of cancer death in
both Europe and the US [1,2]. Advanced age is the most
significant risk factor for diagnosis of CRC, as the vast
majority of patients are diagnosed when 65 and older
with a peak incidence of 415.9 cases per 100,000 in those
85 and older [3]. Despite advances in screening and treat-
ment, stage at diagnosis remains the most important pre-
dictor of mortality. The five-year survival rate for localized
disease is 90.4%, but only 39% of CRCs are diagnosed at
this early stage [3]. Of those diagnosed with metastatic
disease, less than 10% are still alive after 5 years [3].
Since stage at diagnosis plays a significant role in CRC sur-
vival, understanding which factors contribute to a more
advanced stage at diagnosis is vital to improving overall
survival. Potential factors include comorbidity, age, and
race. These factors are known to influence cancer out-
comes at least in terms of receipt of standard therapy,
which in turn, likely influences survival [4-10]. While the
relationship between delivery of treatment and these fac-
tors has been established, the association between comor-
bidity, age, race, and stage at diagnosis of CRC is less clear
(Figure 1).
Access to health care and health insurance has been asso-
ciated with disparities in cancer survival and late stage of
diagnosis [11,12]. The purpose of this analysis is to
describe the association between stage at diagnosis and
comorbidity, age, and race in patients with CRC, and the
influence that the healthcare system has on this associa-
tion. Two US health systems, fee for service (FFS) and the
Veterans Administration (VA), were selected because they
allow assessment of predictors of stage of diagnosis that
may be unique to the health system versus the popula-
tion. Healthcare in the United States is provided through
multiple parallel and overlapping systems roughly
divided between commercial, public, and uninsured/self-
pay programs [13]. FFS represents the context where
patients usually have some form of commercial health
insurance to cover most healthcare costs, access to special-
ist care is more easily obtained, and primary care may or
may not be promoted depending upon the type of insur-
ance provider (e.g. managed care, preferred provider
organization) [13]. The VA system provides care to mili-
tary service veterans and their families; it is a closed sys-
tem with access to primary care providers who act as
gatekeepers to specialist care. The VA system is generally
regarded as a US healthcare system where access to care is
less influenced by ability to pay [14]. We hypothesized
that patients with greater comorbidity, older age, and
white race would be more likely to be diagnosed with
early-stage CRC, due to more frequent contact with the
healthcare system. We hypothesized that these differences
would be most prominent in the VA system where access
to high-quality primary care is encouraged [15,16].
Methods
Study Population
The first patient cohort was derived from patients with
CRC enrolled in the Cancer Care Outcomes Research and
Surveillance Consortium (CanCORS), a cohort study to
evaluate the care of patients with newly diagnosed lung or
CRCs recruited in geographically diverse populations and
health care systems [17]. Eligible patients were ≥ 21 years
old and were diagnosed with colorectal adenocarcinoma
within 3 months of enrollment. Approximately 4,920
patients with CRC have been enrolled in CanCORS. Using
the CanCORS database, we identified patients with CRC
Relationship between stage at diagnosis and comorbidity, age, and raceFigure 1
Relationship between stage at diagnosis and comor-
bidity, age, and race. Comorbidity, age, and race are 
known to influence the delivery of stage-appropriate chemo-
therapy, and thereby influence survival. We hypothesized 
(dotted line) that comorbidity and age also influence survival 
by determining stage at diagnosis.Page 2 of 9
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hospitals from 2003 (cohort initiation) to 2007. Of the
approximately 4,920 CRC patients enrolled in the Can-
CORS study, 477 received treatment in the VA health sys-
tem. Of those, 342 had complete chart abstractions at the
time of this analysis, met inclusion criteria (as described
above), and were included in this analysis. Informed con-
sent was obtained from all living patients and a HIPAA
decedent consent waiver was obtained for deceased
patients.
The second patient cohort was taken from community
and academic FFS practices in the Southeastern US, as part
of a larger study designed to examine regional treatment
patterns for metastatic CRC [18]. Eligible patients were
adults diagnosed with metastatic CRC (recurrent or pri-
mary) from January 2003 to June 2006, and treated at one
of ten participating community or academic sites. Medical
records for patients treated prior to 2003 for non-meta-
static CRC were also included, which allowed for assess-
ment of stage at diagnosis. Of 743 charts initially screened
from local Tumor Registry lists, 340 met eligibility criteria
and had abstracted charts available at the time of this
analysis. Informed consent was waived by the Institu-
tional Review Board for this patient cohort. The research
presented was conducted in accordance with the princi-
ples of the Helsinki Declaration [19].
Data Collection
We conducted retrospective review of patient records
selected from two distinct patient populations, as noted
above. Data were abstracted pertaining to race, cancer
diagnosis, stage, age at diagnosis, and presence of comor-
bid illnesses. Stage at diagnosis was determined from
review of pathology reports in concert with radiology and
physician notes. The TNM staging system was used. Stage
at diagnosis was dichotomized to non-metastatic (defined
as ≤ stage III, localized, or regional) and metastatic due to
sample size limitations. Age at diagnosis was recorded in
years for each patient. Race was dichotomized to white
and non-white.
The presence of comorbid conditions was assessed based
on chronic illnesses identified in the Deyo adaptation of
the Charlson comorbidity index [20]. The Charlson index
was developed as a reproducible measure of the prognos-
tic impact of comorbid illnesses [21]. The index has been
validated in oncology populations and has since been
adapted for use with administrative databases [20].
Patient medical records were abstracted for chronic medi-
cal conditions already established at the time of CRC diag-
nosis (Table 1). The conditions were weighted and
patients were assigned a score in accordance with the
Charlson index [21]. The comorbidity score was modelled
as an integer-valued quantitative variable.
Data Analysis
The primary goal of the analysis was to examine associa-
tions between stage at diagnosis and an a priori set of var-
iables (comorbidity, age, and race) using logistic
regression modelling in cohorts selected from two differ-
ent patient populations. The two cohorts were not jointly
analyzed due to differences in patient characteristics from
both studies and overall study design. Results are pre-
sented for each cohort as unadjusted and adjusted odds
ratios with associated 95% confidence intervals and p-val-
ues. Odds ratios and associated confidence intervals are
also presented graphically to facilitate understanding of
the similarities and differences in the patterns of associa-
tion between the cohorts [22]. Linearity assumptions of
continuous covariates (age and comorbidity) were
assessed using graphical techniques and no evidence of
systematic non-linearity was found. Statistical analyses
were performed using SAS for Windows Version 9.1 (SAS
Institute, Cary, NC). Two-sided p-values at the standard
0.05 level were used to determine statistical significance.
Results
Patient Characteristics
Six hundred eighty-two patients met the eligibility criteria
for this analysis (Table 2). The VA cohort was older than
the FFS cohort (mean age ± standard deviation, 67 ± 11
years in the VA versus 61 ± 14 years in FFS). As expected,
Table 1: Charlson Comorbidity Index conditions and weights
Weight Condition
1 Myocardial infarction, Congestive heart failure, Peripheral vascular disease, Cerebrovascular disease, Dementia, Chronic pulmonary 
disease, Rheumatologic disease, Peptic ulcer disease, Chronic liver disease (mild), Diabetes (uncomplicated) 
2 Hemiplegia, Renal disease (moderate or severe), Diabetes with end organ damage, Solid tumor without metastasis, Leukemia or 
lymphoma  
3 Liver disease (moderate or severe)
6 Metastatic solid tumor, AIDS
Weights are determined by 1-year relative risk of mortality associated with presence of the comorbidity. Comorbidity index per patient is 
calculated by the addition of weighted scores as determined by the Charlson index [21].Page 3 of 9
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to the FFS cohort, which was evenly divided by gender.
More VA patients than FFS patients had a Charlson score
≥ 3 (11% VA versus 7% FFS). Both cohorts were predom-
inantly white. The FFS cohort was comprised of a higher
percentage of patients with stage IV disease at diagnosis
due to original intent and design of the study from which
this patient cohort was drawn [18].
Logistic Regression
The statistical results from the logistic regressions are sum-
marized in Table 3 and discussed below.
Influence of Comorbidity
In the VA cohort, higher comorbidity was associated with
non-metastatic stage at diagnosis. This relationship was
maintained after adjusting for age and race (adjusted odds
ratio (OR) 0.76, 95% confidence interval (CI) 0.58–1.00).
In the FFS cohort, however, no relationship was seen
between comorbidity and stage at diagnosis (adjusted OR
1.09, 95% CI 0.82–1.44).
Influence of Age
In both the VA and FFS cohorts, no evidence was found of
an association between stage at diagnosis and age. The
CI's for the OR's in both populations span 1.0 and overlap
each other, indicating that older age was not associated
with stage at diagnosis. These assertions hold whether or
not the results were adjusted for comorbidity and race.
Influence of Race
The influence of race was not statistically significant for
either cohort. The unadjusted and adjusted confidence
intervals for the odds ratios broadly spanned 1.0 for both
cohorts.
Discussion
This analysis provides a health system-based perspective
on the association between stage of CRC diagnosis and
comorbidity, race, and age. Higher comorbidity was asso-
ciated with non-metastatic stage at diagnosis in the VA
cohort, but not in the FFS cohort. Neither age nor race was
associated with stage at diagnosis. The findings may be to
due to multiple factors, some of which were unmeasured
in this analysis.
A critical, comorbidity-related concern in cancer out-
comes relates to how comorbidity influences survival
among cancer patients. Comorbidity is already known to
negatively influence the delivery of stage-appropriate
treatment (Figure 1), and not receiving appropriate ther-
apy will negatively influence survival outcomes [23-29].
As the population ages, the increasing burden of comor-
bid illness will likely play a greater role in cancer treat-
ment-related toxicity and outcomes. Higher comorbidity
has been shown to broaden the survival disparity between
blacks and whites with CRC [24]. Both comorbidity and
advanced age have been associated with worse outcomes
after surgery for CRC [23,25,26,29], decreased referral to
a medical oncologist [23,28], and incomplete courses of
adjuvant chemotherapy [27,30]. By best understanding
where in the cancer care continuum comorbidity, age, and
race exert their greatest influence, we can better determine
how to improve care for patients with comorbid illnesses
and CRC.
In the VA cohort, where increasing comorbidity was asso-
ciated with earlier stage at diagnosis, patients with multi-
ple comorbid illnesses might have more frequent health
care contact and thus benefit from the greater clinical scru-
tiny it provides. Evidence demonstrates that VA patients
are more likely to experience higher quality primary care
than FFS patients; a corollary to increased access to pri-
mary care is an increase in routine chronic and preventive
medical care that may be overlooked in commercial
health systems with less access to primary care. In non-VA
populations, FFS health care might lead to erratic interac-
tion with the health care system as determined by ability
Table 2: Characteristics of patients in both VA and fee-for-service settings.
Characteristic VA patients1 (n = 342) Fee-for-service patients2 (n = 340)
Stage at diagnosis (%)
Metastatic 27 77
Non-metastatic 73 24
Charlson comorbidity score (Mean ± SD) 2.0 ± ± 1.0
Age in years (Mean ± SD) 67 ± ± 14
Gender (%)
Male 98 48
Female 1.7 52
Race (%)
White 63 73
Non-white 37 27
1Missing value summary for VA: race (n = 6); 2Missing value summary for FFS: Charlson (n = 14), age (n = 47), gender (n = 11), race (n = 45),Page 4 of 9
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better with diabetes and hyperlipidemia control than
patients in commercial health systems [15]. VA patients
are more likely to report receiving diabetes education than
those covered by private insurance [31]. Hence, the
increased medical scrutiny inherent when a person has
multiple comorbidities coupled with a health system that
provides easy access to primary care providers might
ensure delivery of age-appropriate screening or might lead
to the incidental diagnosis of cancer through blood tests
or studies ordered for other purposes.
Other factors may explain the relationship between
comorbidity and stage observed in the VA cohort and not
in the FFS cohort. Most notably, the difference might be
due to differences in the two cohorts. The VA cohort was
older, predominantly male, and carried a higher burden
of comorbid illnesses than the FFS cohort. This difference
between the VA and non-VA cohorts in our analysis is rep-
resentative of the VA and non-VA populations as a whole
[32-35]. The association might be influenced by the
comorbid conditions themselves, leading to a varied
influence of comorbidity on stage based more upon pop-
ulation and less on health system. For example, symp-
toms attributed to comorbid illnesses might actually be
arising from a neglected, evolving malignancy [36]. Sec-
ond, the pathophysiology of the comorbid illness or its
treatment might contribute to the development or pro-
gression of the cancer. For example, a growing body of
data has demonstrated an association between chronic
insulin therapy and development of CRC among patients
with type II diabetes mellitus [37]. Such factors might
have diminished (in the VA group) or nullified (in the FFS
group) the effect of comorbidity on stage at diagnosis.
Another factor may have been the definition of the FFS
cohort. Eligible patients had metastatic disease during
2003–2006, although their prior non-metastatic period
was also considered. As a result, the cohort was enriched
with patients who were stage IV at diagnosis. This group
may have less screening and healthcare involvement at
baseline, and the impact of comorbidity status may have
been diluted. Nonetheless, this group still had a quarter of
patients who were non-metastatic at diagnosis.
In our analysis, race and age were not influential factors in
the stage of CRC diagnosis. Age was not influential likely
because numeric age is less important clinically when the
degree of comorbidity is measured. In other words, older
patients without significant comorbidity should have sim-
ilar clinical outcomes than relatively younger patients
without comorbidity. For instance, when older patients
receive chemotherapy, they are able to tolerate and
respond to treatment as well as their younger counterparts
[38-41]. The lack of interaction with race and stage at diag-
nosis might be due to a similar process. Bach et al found
that after controlling for population mortality (non-can-
cer related death), the difference in cancer-related mortal-
ity between blacks and white was diminished [24]. The
racial differences in stage at diagnosis might be reduced
when adjusted for comorbidity. We did not, however,
account for differences in socioeconomic status, which
might have also influenced the role of race.
In framing the significance of our findings, the limitations
of this study must be discussed. First, in terms of catego-
rizing comorbidity, we chose to use the Charlson index,
which has been validated in the oncology setting. Despite
being updated, the index was created in 1984 and based
on admissions to a hospital over a one-month period
[20,21], which brings into question the generalizability of
the index to cancer diagnosis and treatment today [42].
The Charlson index does not grade severity of comorbid-
ity, nor does it capture functional disability. It might not
Table 3: Association of metastatic stage of colorectal cancer diagnosis with comorbidity, age, and race in two patient cohorts
Characteristic VA FFS
OR (95% CI) p-value OR (95% CI) p-value
Comorbidity
Unadjusted 0.78 (0.61, 1.00) 0.04 1.08 (0.82, 1.42) 0.59
Adjusted 0.76 (0.58, 1.00) 0.045 1.09 (0.82, 1.44) 0.57
Age (≥ 70 years)
Unadjusted 0.98 (0.79, 1.23) 0.88 0.97 (0.80, 1.18) 0.76
Adjusted 1.08 (0.85, 1.36) 0.54 0.96 (0.78, 1.17) 0.67
Race (white)
Unadjusted 0.80 (0.49, 1.31) 0.39 1.12 (0.61, 2.08) 0.72
Adjusted 0.83 (0.51, 1.37) 0.47 1.12 (0.60, 2.09) 0.72
Adjusted odds ratios were calculated from a multivariable logistic regression model that included Charlson comorbidity score (modelled as an 
integer-valued quantitative variable), age at diagnosis (expressed in years), and race (white vs non-white). The unadjusted and adjusted odds ratios, 
shown here with associated 95% confidence intervals and p-values, are for a single unit increase in comorbidity, a decade increase in age, and the 
comparison of white vs. non-white for race. Final n for VA adjusted model = 336 (91 metastatic, 245 non-metastatic), final n for FFS adjusted model 
= 270 (198 metastatic, 72 non-metastatic).Page 5 of 9
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to a cancer population. On the other hand, the ease of use,
reliability, and content validity of the index make it a rea-
sonable choice [42].
Second, asymptomatic screening was not addressed as a
variable in this study as patient screening information was
not available for both patient cohorts. Patients with a high
comorbidity index might be less likely to undergo cancer
screening due to an increased risk for non-cancer-related
mortality. If this were the case, the relationship between
comorbidity and stage at diagnosis might be less impor-
tant than the relationship between comorbidity and
receipt of screening, as delayed screening could contribute
to later stage at diagnosis. However, studies conducted in
both VA and non-VA populations have shown that
patients are screened for CRC regardless of comorbidity
status, thereby suggesting that no relationship exists
between degree of comorbidity and rates of asymptomatic
screening [43-46]. If screening rates are not influenced by
comorbidity, then stage at diagnosis becomes the next
most important variable for investigation. Furthermore, if
younger, healthier patients are more likely to be screened
for CRC, then this analysis should have found that
younger, healthier patients present with non-metastatic
disease, and older, sicker patients present with metastatic
disease. It did not.
This analysis does not explicitly address access to screen-
ing studies such as colonoscopy. Multiple factors have
been associated with access or adherence to colorectal
cancer screening, including age, education, insurance sta-
tus, and a usual source of care [47]. Our presented data
cannot address these characteristics completely, though
the literature supports the assumption that VA patients
enjoy greater access to many aspects of primary care than
Medicare fee-for-service and privately insured patients
[15,16,31]. While specific data is not available for our
sample, the rate of CRC screening with endoscopy is fairly
equivalent between VA and non-VA populations [48,49].
This study has strengths that overcome limitations of
prior studies. First, we provide consistent data from two
distinct health care systems. Our study is the first to exam-
ine the relationship between comorbidity, age and stage at
diagnosis in the VA health system. As receipt of care in this
system is less dependent on ability to pay, it serves as a
useful control for the inability to access appropriate can-
cer care [50]. Second, this study does not dichotomize
comorbidity, but models it as an integer-valued quantita-
tive variable (0–≥ 3) with Charlson score ≥ 3 equated with
severe comorbidity. A score of ≥ 3 predicts a significantly
greater risk of non-cancer-related mortality over a one-
year period [21]. A prior study demonstrated a slightly
higher prevalence of comorbidity in patients diagnosed
with early-stage (Dukes' A) CRC, but this study dichot-
omized comorbidity with a cut point of ≥ 1 [51]. A study
by Gonzalez et al found the opposite: patients with any
comorbid condition (Charlson score ≥ 1 vs. 0) were more
likely to be diagnosed at late-stage, though interestingly,
this finding did not persist with a Charlson score of ≥ 2
[52]. Based on these findings, we chose not to dichot-
omize comorbidity. This more quantitative use of the
comorbidity index, as opposed to simply measuring pres-
ence versus absence of any comorbidity, might provide a
more clinically-useful model when assessing the role of a
comorbidity index on the diagnosis, treatment, and out-
comes of cancer. A third strength of our study lies in our
ability to measure comorbidity. Studies examining stage
with larger cohorts obtained from cancer registries such as
the Surveillance, Epidemiology, and End Results (SEER)
database do not have access to comorbidity data.
Our exploratory results help to focus future efforts on
improving CRC outcomes. As the association between
comorbidity and cancer outcomes becomes clearer, future
prospective studies should examine where in the patient's
cancer care trajectory a specific comorbid illness might
impact outcomes [53]. For example, among patients with
breast cancer, studies have shown that only certain comor-
bid illnesses (such as diabetes) contribute to a later stage
at diagnosis, while others (such as cardiovascular disease)
do not [54]. Our exploratory findings should encourage
further investigation into how comorbid illnesses, and
not just comorbidity indices, impact diagnosis, treatment,
and survival. If patients are even more likely to be diag-
nosed at early stage in the setting of comorbid illness, it
becomes even more important to develop CRC treatment
strategies that accommodate comorbidities. Future analy-
sis will ask similar questions of the complete, multi-
health system CanCORS sample, which includes approxi-
mately 10,000 lung and colorectal cancer patients. Socio-
economic characteristics, including income and
education, should also be explored in conjunction with
comorbidity. These factors cannot be appropriately inves-
tigated through SEER-Medicare linked datasets but can be
explored via CanCORS.
As cancer treatment improves, more patients are living
longer. As a result, more attention needs to be paid to the
role of comorbidity and the patient's overall health as
comorbidity might actually play a greater role in survival
than the cancer, itself. Studies have shown that some can-
cer patients might be less likely to adopt diet, exercise and
other healthy lifestyle changes after a cancer diagnosis
[55]. Future interventional studies among cancer patients
might investigate how better controlling health habits and
comorbid illnesses might improve health-related quality
of life and cancer-related survival outcomes. Data from
this study suggests that the role of the health system andPage 6 of 9
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timing of diagnosis of CRC; similarly, access to primary
and routine healthcare will be important for maintenance
of health in the cancer survivorship period.
Currently, oncologists are treating older or frailer patients
based on clinical trial data from younger, healthier
patients [56-58]. If a better understanding is gained as to
the role of comorbidities in cancer outcomes, patients
with greater comorbidity and advanced age could be
enrolled and evaluated separately in clinical trials in order
to understand how they truly benefit from advances in
cancer therapy. Such diversification of the clinical trial
population would produce clinical trial data that is more
representative of the typical cancer patient who might not
be otherwise eligible for a clinical trial but might still ben-
efit from some form of treatment.
Conclusion
In this analysis of patients with CRC treated in two dis-
tinct health systems, we found that higher comorbidity is
related to earlier stage of CRC diagnosis for VA patients.
This finding might be the result of many factors, some
unmeasured in this analysis. One factor might be the way
care is delivered within certain US health systems, where
access to care is less related to ability to pay and primary
care is promoted. Future studies should be designed to
focus on the impact of specific comorbidities on both
stage at diagnosis and survival outcomes.
List of abbreviations
CanCORS: Cancer Care Outcomes Research and Surveil-
lance Consortium; VA: Veterans Administration; FFS: fee-
for-service; OR: odds ratio; CI: confidence interval; US:
United States; SEER: Surveillance, Epidemiology, and End
Results.
Competing interests
The fee-for-service portion of this chart review study was
funded through an Outcomes Research service agreement
with Pfizer, Inc., as an assessment of patterns of care
among patients with metastatic CRC. Pfizer, Inc. does not
have access to individual data nor authority to prohibit
publication of results. None of the authors have a conflict
of interest to report relevant to this Pfizer funding rela-
tionship.
Authors' contributions
SYZ conceived of this analysis, participated in its design,
and drafted the manuscript. APA contributed data from
the FFS patient cohort, participated in study conception
and design, assisted in data interpretation, and helped
draft the manuscript. DHA performed the data analysis
and helped draft the manuscript. SCG designed and
directed the statistical analysis, and helped draft the man-
uscript. JEM assisted with data management. JEH contrib-
uted to developing the analytic plan. JTK assisted with
data management and participated in study design. LLZ
assisted with data management and analytic design. MBP
participated in analytic design, data management, and
drafting of the manuscript. DTP contributed to analysis
conception, design, data interpretation, and helped draft
the manuscript.
Acknowledgements
The work of the CanCORS consortium was supported by grants from the 
National Cancer Institute (NCI) to the Statistical Coordinating Center 
(U01 CA093344) and the NCI supported Primary Data Collection and 
Research Centers (Dana-Farber Cancer Institute/Cancer Research Net-
work U01 CA093332, Harvard Medical School/Northern California Cancer 
Center U01 CA093324, RAND/UCLA U01 CA093348, University of Ala-
bama at Birmingham U01 CA093329, University of Iowa U01 CA.01013, 
and the University of North Carolina U01 CA 093326), by AHRQ 03-
438MO-03, and by a Department of Veteran's Affairs grant to the Durham 
VA Medical Center HSRD CRS 02-164.
The fee-for-service portion of this chart review study was funded through 
an Outcomes Research service agreement with Pfizer, Inc., as an assess-
ment of patterns of care among patients with metastatic CRC.
References
1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Esti-
mates of the cancer incidence and mortality in Europe in
2006.  Ann Oncol 2007, 18(3):581-592.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statis-
tics, 2007.  CA Cancer J Clin 2007, 57:34-66.
3. National Cancer Institute SEER Cancer Statistics Review
1975–2003   [http://seer.cancer.gov/csr/1975_2003/results_merged/
sect_06_colon_rectum.pdf]
4. Firat S, Pleister A, Byhardt RW, Gore E: Age is independent of
comorbidity influencing patient selection for combined
Comorbidity, Age, and Race: Impact on StageFigure 2
Comorbidity, Age, and Race: Impact on Stage. The 
impact of comorbidity, age, and race on stage at diagnosis is 
measured by the adjusted odds ratios of these factors. The 
odds ratios, shown here with 95% confidence intervals, are 
for a single unit increase in comorbidity, a decade increase in 
age, and the comparison of white vs. non-white for race. The 
relationship between comorbidity and stage among VA 
patients is statistically significant, but the upper bounds of the 
CI rounds to 1.0 (0.998).
Earlier stage Later stagePage 7 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:345 http://www.biomedcentral.com/1471-2407/8/345modality therapy for treatment of stage III nonsmall cell
lung cancer (NSCLC).  Am J Clin Oncol 2006, 29(3):252-257.
5. Hawfield A, Lovato J, Covington D, Kimmick G: Retrospective
study of the effect of comorbidity on use of adjuvant chemo-
therapy in older women with breast cancer in a tertiary care
setting.  Crit Rev Oncol Hematol 2006, 59(3):250-255.
6. Lemmens VE, van Halteren AH, Janssen-Heijnen ML, Vreugdenhil G,
Repelaer van Driel OJ, Coebergh JW: Adjuvant treatment for
elderly patients with stage III colon cancer in the southern
Netherlands is affected by socioeconomic status, gender,
and comorbidity.  Ann Oncol 2005, 16(5):767-772.
7. Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR:
The influence of comorbidities, age, and performance status
on the prognosis and treatment of patients with metastatic
carcinomas of unknown primary site: a population-based
study.  Cancer 2006, 106(9):2058-2066.
8. Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney
MM: Patterns of care for adjuvant therapy in a random pop-
ulation-based sample of patients diagnosed with colorectal
cancer.  Am J Gastroenterol 2006, 101(10):2308-2318.
9. Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Craw-
ford J, Dale DC, Lyman GH: Social and racial differences in
selection of breast cancer adjuvant chemotherapy regimens.
J Clin Oncol 2007, 25(18):2522-2527.
10. Ramsey SD, Howlader N, Etzioni RD, Donato B: Chemotherapy
use, outcomes, and costs for older persons with advanced
non-small-cell lung cancer: evidence from surveillance, epi-
demiology and end results.  Medicare. J Clin Oncol 2004,
22(24):4971-4978.
11. Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P,
Siegel R, Stewart A, Jemal A: Association of insurance with can-
cer care utilization and outcomes.  CA Cancer J Clin 2008,
58(1):9-31.
12. Halpern MT, Bian J, Ward EM, Schrag NM, Chen AY: Insurance sta-
tus and stage of cancer at diagnosis among women with
breast cancer.  Cancer 2007, 110(2):403-411.
13. Health, United States   [http://www.cdc.gov/nchs/data/hus/
hus07.pdf]
14. Oddone EZ, Petersen LA, Weinberger M, Freedman J, Kressin NR:
Contribution of the Veterans Health Administration in
understanding racial disparities in access and utilization of
health care: a spirit of inquiry.  Med Care 2002, 40(1
Suppl):I3-13.
15. Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, Herman
WH, Marrero DG, Narayan KM, Safford MM, et al.: Diabetes care
quality in the Veterans Affairs Health Care System and com-
mercial managed care: the TRIAD study.  Ann Intern Med 2004,
141(4):272-281.
16. Jha AK, Perlin JB, Kizer KW, Dudley RA: Effect of the transforma-
tion of the Veterans Affairs Health Care System on the qual-
ity of care.  N Engl J Med 2003, 348(22):2218-2227.
17. Ayanian JZ, Chrischilles EA, Fletcher RH, Fouad MN, Harrington DP,
Kahn KL, Kiefe CI, Lipscomb J, Malin JL, Potosky AL, et al.: Under-
standing cancer treatment and outcomes: the Cancer Care
Outcomes Research and Surveillance Consortium.  J Clin
Oncol 2004, 22:2992-2996.
18. Abernethy AP, Patwardhan M, Herndon JE, Dowell J, Rowe K, Martin
MG, Zafar YMAM: Tracking performance: Can oncology prac-
tices respond to the new quality measures?  American Society of
Clinical Oncology Gastrointestinal Cancers Symposium: 2007; Orlando, FL
2007.
19. World Medical Association Declaration of Helsinki: Ethical
Principles for Medical Research Involving Human Subjects
[http://www.wma.net/e/policy/b3.htm]
20. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity
index for use with ICD-9-CM administrative databases.  J Clin
Epidemiol 1992, 45:613-619.
21. Charlson ME, Pompei P, Ales Kl, MacKenzie CR: A new method of
classifying prognostic comorbidity in longitudinal studies:
development and validation.  J Chron Dis 1987, 40:373-383.
22. Galbraith RF: A note on graphical presentation of estimated
odds ratios from several clinical trials.  Statistics in medicine 1988,
7(8):889-894.
23. Anthony T, Hynan LS, D R: The association of pretreatment
health-related quality of life with surgical complications for
patients undergoing open surgical resection for colorectal
cancer.  Ann Surg 2003, 238:690-696.
24. Bach PB, Schrag D, Brawley OW, et al.: Survival of whites and
blacks after a cancer diagnosis.  JAMA 2002, 287:2106-2113.
25. Colorectal Cancer Collaborative Group: Surgery for colorectal
cancer in elderly patients: a systematic review.  Lancet 2000,
356:968-974.
26. Luo R, Giordano SH, Freeman JL, et al.: Referral to medical oncol-
ogy: a crucial step in the treatment of older patients with
stage III colon cancer.  Oncologist 2006, 11:1025-1033.
27. Neugent AI, Matasar M, Wang X, et al.: Duration of adjuvant
chemotherapy for colon cancer and survival among the eld-
erly.  J Clin Oncol 2006, 24:2368-2375.
28. Ong S, Watters JM, E G: Predictors for referral for adjuvant
therapy for colorectal cancer.  Can J Surg 2005, 48:225-229.
29. Ouellette JR, Small DG, PM T: Evaluation of Charlson-Age
Comorbidity Index as predictor of morbidity and mortality
in patients with colorectal carcinoma.  J Gastrointest Surg 2004,
8:1061-1067.
30. Gross CP, McAvay GJ, Guo Z, Tinetti ME: The impact of chronic
illnesses on the use and effectiveness of adjuvant chemother-
apy for colon cancer.  Cancer 2007, 109(12):2410-2419.
31. Nelson KM, Chapko MK, Reiber G, Boyko EJ: The association
between health insurance coverage and diabetes care; data
from the 2000 Behavioral Risk Factor Surveillance System.
Health Serv Res 2005, 40(2):361-372.
32. Medical Expenditure Panel Survey, Complete Set of Health
Insurance Coverage Series in PDF Format, first half of 2001
[http://www.meps.ahrq.gov/mepsweb/data_stats/summ_tables/hc/
hlth_insr/2001/alltables.pdf]
33. 2001 National Survey of Veterans, Demographics   [http://
www1.va.gov/vetdata/docs/Table_11_112.pdf]
34. 2001 National Survey of Veterans, Health Status   [http://
www1.va.gov/vetdata/docs/Table_31_310.pdf]
35. Wilson NJ, Kizer KW: The VA health care system: An unrecog-
nized safety net.  Health Aff 1997, 16:200-204.
36. Crawford J, Cohen HJ: Aging and neoplasia.  Annu Rev Gerontol Ger-
iatr 1984, 4:3-32.
37. Yang YX, Hennessy S, Lewis JD: Insulin therapy and colorectal
cancer risk among type 2 diabetes mellitus patients.  Gastro-
enterology 2004, 127(4):1044-1050.
38. Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford
J, Lyman GH: Dose intensity and hematologic toxicity in older
cancer patients receiving systemic chemotherapy.  Cancer
2007, 110(7):1611-1620.
39. Berardi R, Saladino T, Mari D, Silva RR, Scartozzi M, Verdecchia L,
Onofri A, Cascinu S: Elderly patients with advanced colorectal
cancer: tolerability and activity of chemotherapy.  Tumori
2005, 91(6):463-466.
40. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand
C, Andre T, Rothenberg ML, Green E, Sargent DJ: Pooled analysis
of safety and efficacy of oxaliplatin plus fluorouracil/leucov-
orin administered bimonthly in elderly patients with color-
ectal cancer.  J Clin Oncol 2006, 24(25):4085-4091.
41. Sanoff HK, Bleiberg H, Goldberg RM: Managing older patients
with colorectal cancer.  J Clin Oncol 2007, 25(14):1891-1897.
42. Hall SF: A user's guide to selecting a comorbidity index for
clinical research.  J Clin Epidemiol 2006, 59:849-855.
43. Cooper GS, Fortinsky RH, Hapke R, Landefeld CS: Primary care
physician recommendations for colorectal cancer screening.
Patient and practitioner factors.  Arch Int Med 1997,
157:1946-1950.
44. Fisher DA, Judd L, Sanford NS: Inappropriate colorectal cancer
screening: findings and implications.  Am J Gastroenterol 2005,
100(11):2526-2530.
45. Garman KS, Jeffreys A, Coffman C, et al.: Colorectal cancer
screening, comorbidity, and follow-up in elderly patients.  Am
J Med Sci 2006, 332:159-163.
46. Sultan S, Conway J, Edelman D, Dudley T, Provenzale D: Colorectal
cancer screening in young patients with poor health and
severe comorbidity.  Arch Intern Med 2006, 166(20):2209-2214.
47. Subramanian S, Klosterman M, Amonkar MM, Hunt TL: Adherence
with colorectal cancer screening guidelines: a review.  Prev
Med 2004, 38(5):536-550.
48. Dolan NC, Ferreira MR, Fitzgibbon ML, Davis TC, Rademaker AW,
Liu D, Lee J, Wolf M, Schmitt BP, Bennett CL: Colorectal cancerPage 8 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:345 http://www.biomedcentral.com/1471-2407/8/345Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
screening among African-American and white male veter-
ans.  Am J Prev Med 2005, 28(5):479-482.
49. Colorectal cancer test use among persons aged > or = 50
years – United States, 2001.  MMWR Morb Mortal Wkly Rep 2003,
52(10):193-196.
50. Dominitz JA, Samsa GP, Landsman P, Provenzale D: Race, treat-
ment, and survival among colorectal carcinoma patients in
an equal-access medical system.  Cancer 1998, 82:2312-2320.
51. De Marco MF, Janssen-Heijnen ML, Heijden LH van der, Coebergh
JW: Comorbidity and colorectal cancer according to subsite
and stage: a population-based study.  Eur J Cancer 2000,
36:95-99.
52. Gonzalez EC, Ferrante JM, Van Durme DJ, Pal N, Roetzheim RG:
Comorbid illness and the early detection of cancer.  South Med
J 2001, 94:913-920.
53. Geraci JM, Escalante CP, Freeman JL, Goodwin JS: Comorbid dis-
ease and cancer: the need for more relevant conceptual
models in health services research.  J Clin Oncol 2005,
23:7399-7404.
54. Fleming ST, Pursley HG, Newman B, Pavlov D, Chen K: Comorbid-
ity as a predictor of stage of illness for patients with breast
cancer.  Med Care 2005, 43(2):132-140.
55. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM: Riding
the crest of the teachable moment: promoting long-term
health after the diagnosis of cancer.  J Clin Oncol 2005,
23(24):5814-5830.
56. Langer CJ: Neglected and underrepresented subpopulations:
elderly and performance status 2 patients with advanced-
stage non-small-cell lung cancer.  Clin Lung Cancer
2006:S126-137.
57. Adams-Campbell LL, Ahaghotu C, Gaskins M, Dawkins FW, Smoot D,
Polk OD, Gooding R, DeWitty RL: Enrollment of African Amer-
icans onto clinical treatment trials: study design barriers.  J
Clin Oncol 2004, 22:730-734.
58. Aapro MS, Kohne CH, Cohen HJ, Extermann M: Never too old?
Age should not be a barrier to enrollment in cancer clinical
trials.  Oncologist 2005, 10:198-204.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/345/pre
pubPage 9 of 9
(page number not for citation purposes)
